Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 171

1.

Different infusion durations for preventing platinum-induced hearing loss in children with cancer.

van As JW, van den Berg H, van Dalen EC.

Cochrane Database Syst Rev. 2016 Aug 8;(8):CD010885. doi: 10.1002/14651858.CD010885.pub3. Review. Update in: Cochrane Database Syst Rev. 2018 Jul 05;7:CD010885.

PMID:
27498707
2.

Different infusion durations for preventing platinum-induced hearing loss in children with cancer.

van As JW, van den Berg H, van Dalen EC.

Cochrane Database Syst Rev. 2018 Jul 5;7:CD010885. doi: 10.1002/14651858.CD010885.pub4. Review.

3.

Different infusion durations for preventing platinum-induced hearing loss in children with cancer.

van As JW, van den Berg H, van Dalen EC.

Cochrane Database Syst Rev. 2014 Jun 26;(6):CD010885. doi: 10.1002/14651858.CD010885.pub2. Review. Update in: Cochrane Database Syst Rev. 2016;8:CD010885.

PMID:
24968257
4.

Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.

van As JW, van den Berg H, van Dalen EC.

Cochrane Database Syst Rev. 2019 May 7;5:CD009219. doi: 10.1002/14651858.CD009219.pub5.

PMID:
31063591
5.

Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.

van As JW, van den Berg H, van Dalen EC.

Cochrane Database Syst Rev. 2014 Jul 1;(7):CD009219. doi: 10.1002/14651858.CD009219.pub3. Review.

PMID:
24984156
6.

Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.

van As JW, van den Berg H, van Dalen EC.

Cochrane Database Syst Rev. 2012 May 16;(5):CD009219. doi: 10.1002/14651858.CD009219.pub2. Review. Update in: Cochrane Database Syst Rev. 2014;(7):CD009219.

PMID:
22592737
7.

Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.

van As JW, van den Berg H, van Dalen EC.

Cochrane Database Syst Rev. 2016 Sep 27;9:CD009219. doi: 10.1002/14651858.CD009219.pub4. Review. Update in: Cochrane Database Syst Rev. 2019 May 07;5:CD009219.

8.

Platinum-induced hearing loss after treatment for childhood cancer.

van As JW, van den Berg H, van Dalen EC.

Cochrane Database Syst Rev. 2016 Aug 3;(8):CD010181. doi: 10.1002/14651858.CD010181.pub2. Review.

9.

Rapid COJEC versus standard induction therapies for high-risk neuroblastoma.

Peinemann F, Tushabe DA, van Dalen EC, Berthold F.

Cochrane Database Syst Rev. 2015 May 19;(5):CD010774. doi: 10.1002/14651858.CD010774.pub2. Review.

PMID:
25989478
10.

Platinum-containing regimens for metastatic breast cancer.

Egger SJ, Willson ML, Morgan J, Walker HS, Carrick S, Ghersi D, Wilcken N.

Cochrane Database Syst Rev. 2017 Jun 23;6:CD003374. doi: 10.1002/14651858.CD003374.pub4. Review.

11.

Low bacterial diet versus control diet to prevent infection in cancer patients treated with chemotherapy causing episodes of neutropenia.

van Dalen EC, Mank A, Leclercq E, Mulder RL, Davies M, Kersten MJ, van de Wetering MD.

Cochrane Database Syst Rev. 2016 Apr 24;4:CD006247. doi: 10.1002/14651858.CD006247.pub3. Review.

12.

High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.

Yalçin B, Kremer LC, van Dalen EC.

Cochrane Database Syst Rev. 2015 Oct 5;(10):CD006301. doi: 10.1002/14651858.CD006301.pub4. Review.

PMID:
26436598
13.

Chemotherapy for children with medulloblastoma.

Michiels EM, Schouten-Van Meeteren AY, Doz F, Janssens GO, van Dalen EC.

Cochrane Database Syst Rev. 2015 Jan 1;1:CD006678. doi: 10.1002/14651858.CD006678.pub2. Review.

PMID:
25879092
14.

High-dose chemotherapy and autologous haematopoietic stem cell rescue for children with high-risk neuroblastoma.

Yalçin B, Kremer LC, Caron HN, van Dalen EC.

Cochrane Database Syst Rev. 2013 Aug 22;(8):CD006301. doi: 10.1002/14651858.CD006301.pub3. Review. Update in: Cochrane Database Syst Rev. 2015;(10):CD006301.

PMID:
23970444
15.

Systemic treatments for the prevention of venous thrombo-embolic events in paediatric cancer patients with tunnelled central venous catheters.

Schoot RA, Kremer LC, van de Wetering MD, van Ommen CH.

Cochrane Database Syst Rev. 2013 Sep 11;(9):CD009160. doi: 10.1002/14651858.CD009160.pub2. Review.

PMID:
24026801
16.

Iodine-131-meta-iodobenzylguanidine therapy for patients with newly diagnosed high-risk neuroblastoma.

Kraal KC, van Dalen EC, Tytgat GA, Van Eck-Smit BL.

Cochrane Database Syst Rev. 2017 Apr 21;4:CD010349. doi: 10.1002/14651858.CD010349.pub2. Review.

17.

Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.

Cheuk DK, Sieswerda E, van Dalen EC, Postma A, Kremer LC.

Cochrane Database Syst Rev. 2016 Aug 23;(8):CD008011. doi: 10.1002/14651858.CD008011.pub3. Review.

PMID:
27552363
18.

Early and late adverse renal effects after potentially nephrotoxic treatment for childhood cancer.

Kooijmans EC, Bökenkamp A, Tjahjadi NS, Tettero JM, van Dulmen-den Broeder E, van der Pal HJ, Veening MA.

Cochrane Database Syst Rev. 2019 Mar 11;3:CD008944. doi: 10.1002/14651858.CD008944.pub3.

PMID:
30855726
19.

Hypothalamic-pituitary-adrenal (HPA) axis suppression after treatment with glucocorticoid therapy for childhood acute lymphoblastic leukaemia.

Rensen N, Gemke RJ, van Dalen EC, Rotteveel J, Kaspers GJ.

Cochrane Database Syst Rev. 2017 Nov 6;11:CD008727. doi: 10.1002/14651858.CD008727.pub4. Review.

20.

Low bacterial diet versus control diet to prevent infection in cancer patients treated with chemotherapy causing episodes of neutropenia.

van Dalen EC, Mank A, Leclercq E, Mulder RL, Davies M, Kersten MJ, van de Wetering MD.

Cochrane Database Syst Rev. 2012 Sep 12;(9):CD006247. doi: 10.1002/14651858.CD006247.pub2. Review. Update in: Cochrane Database Syst Rev. 2016;4:CD006247.

PMID:
22972091

Supplemental Content

Support Center